Brief: Biosenic Receives Key European Patent From EPO For Further Therapeutic Development
April 18 (Reuters) - Bone Therapeutics SA BIOS.BR :
* BIOSENIC RECEIVES KEY EUROPEAN PATENT FROM EPO, FOR
FURTHER
THERAPEUTIC DEVELOPMENT IN CANCER, INFECTIOUS AND IMMUNE
DISEASES
Source text for Eikon: ID:nGNEby2kCl
Further company coverage: BIOS.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Biosenic SA
See all newsBrief: Biosenic Says Enterprise Court Of Nivelles Approves Co's Restructuring Plan
Brief: Biosenic Anticipates Having Sufficient Cash To Carry Out Its Business Objectives Until Q3 2024
Brief: BioSenic Patent Granted In Canada For Broader Protection Of ATO Therapeutic Platform
Brief: Biosenic Files For Additional Patent Protection For Osteoarthritis Drug
Brief: BioSenic Signs New Binding Term Sheet With Phebra PTY Ltd